Description
Mirabegron is not indicated for colorectal cancer; it is used to treat overactive bladder. It has no clinical relevance in the treatment of CCR and should not be considered as part of any therapeutic regimen for this condition.
Mechanism of Action
Mirabegron is a selective ?3-adrenoceptor agonist that increases intracellular cAMP levels in smooth muscle cells, leading to relaxation of the bladder detrusor muscle.
Side Effects
Dry mouth; urinary tract infection; upper respiratory tract infection
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT06534762
med_phase_prefix2
Recruiting
Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
China